Can Abbott Laboratories Breathe Life into This Struggling Business?

Few health-care companies reach as widely as Abbott Labs . This tried-and-true diversified giant operates across markets such as nutrition, diagnostics, and medical devices, and it's long been a favorite for investors in the long term. However, Abbott's recently stumbled in its generic-drug-making business: The company saw sales from this unit fall 6.6% in its most recent quarter.

Abbott's not a company to let problems stick around for long, however, and the firm's moved fast to shore up its generics unit by joining the big pharma buyout party that's rolled along in 2014. The company announced recently that it will buy Chilean drugmaker CFR Pharmaceuticals in a nearly $3 billion acquisition, a move that could also inject Abbott with a much-needed dose of emerging market growth.

Can CFR and the growing South American pharmaceutical market make up for Abbott's generic sales drop? Find out the latest about this health-care giant in the following video, as Motley Fool contributor Dan Carroll takes you through the CFR acquisition-and what the next step for Abbott Labs could be.

Will this stock be your next multibagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with amazing potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303%! You don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

The article Can Abbott Laboratories Breathe Life into This Struggling Business? originally appeared on

Dan Carroll and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story